Anixa Biosciences (ANIX) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nkarta (NKTX) has outperformed Anixa Biosciences (ANIX) over the past year, losing 36.9% versus a loss of 43.8%. Over five years, ANIX leads with a -38.7% price change compared with -93.0% for NKTX. Anixa Biosciences is the larger company by market cap ($84.8 million vs $81.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | NKTX |
|---|---|---|
| Share price | $2.44 | $1.14 |
| Market cap | $84.82M | $81.29M |
| 1-day change | -6.15% | +1.34% |
| YTD return | -21.79% | -38.65% |
| 1-year return | -43.78% | -36.94% |
| 5-year return | -38.69% | -93.05% |
| EPS (TTM) | $-0.32 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-10.93M | $-104.08M |
| 52-week high | $5.46 | $3.72 |
| 52-week low | $2.32 | $1.11 |
| Distance from 52-week high | -55.31% | -69.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.31% | +825.11% |
| Average volume | 282.29K | 1.02M |
| Shares outstanding | 34.76M | 71.62M |
| Employees | 4 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees
ANIX vs NKTX FAQ
Which is bigger, Anixa Biosciences or Nkarta?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $81.29M for Nkarta (NKTX).
Which stock has performed better over the past year, ANIX or NKTX?
NKTX returned -36.94% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.